ArticleSchizophrenia bulletin2014
Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia.
Article in Schizophrenia bulletin, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 5 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- The Potential Use of Peripheral Blood Mononuclear Cells as Biomarkers for Treatment Response and Outcome Prediction in Psychiatry: A Systematic Review.Molecular diagnosis & therapy · 2021Pooled it
- Effects of inflammation on the kynurenine pathway in schizophrenia - a systematic review.Journal of neuroinflammation · 2020Pooled it
- Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis.Schizophrenia bulletin · 2019Pooled it
- Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis.The international journal of neuropsychopharmacology · 2017Pooled it
- Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.Schizophrenia bulletin · 2013Pooled it
- Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia.Brain imaging and behavior · 2021Trial
- Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial.Schizophrenia bulletin · 2021Trial
- A Multicentre, Randomised, Controlled Trial of a Combined Clinical Treatment for First-Episode Psychosis.International journal of environmental research and public health · 2021Trial
- Higher peripheral blood homocysteine levels are associated with schizophrenia: evidence from a case-control study and a meta-analysis.Molecular psychiatry · 2026Article
- Alterations in GABAergic Interneurons, Neuroinflammation, and Epigenetics: Potential Targets for Therapeutic Strategies in Schizophrenia.Current neuropharmacology · 2026Article
- Magnesium and Zinc in Schizophrenia.Biomedicines · 2025Review
- Clinical Relevance of Peripheral Interleukins in Drug-Naive First-Episode Psychosis: Symptom-Specific Associations from the PANSS Dimensions.Brain sciences · 2025Article
- Association of TNF and TLR2 genes with blood parameter levels in Mexican patients with schizophrenia.BMC psychiatry · 2025Article
- Association between white blood cell counts and the efficacy on cognitive function after rTMS intervention in schizophrenia.Schizophrenia (Heidelberg, Germany) · 2025Article
- Can Non-specific Blood Inflammatory Biomarkers Predict Recovery in Acute Transient Psychotic Disorder? A Prospective Observational Study.Indian journal of psychological medicine · 2025Article
- Th17-related cytokines and chemokines are associated with immune dysregulation and severity in schizophrenia.Frontiers in psychiatry · 2025Article
- Blood-based biomarkers in mild behavioral impairment: an updated overview.Frontiers in neurology · 2025Review
- Pioglitazone attenuates behavioral and electrophysiological dysfunctions induced by two-hit model of schizophrenia in adult rodent offspring.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2024Article
- Elevated serum kynurenic acid in individuals with first-episode psychosis and insufficient response to antipsychotics.Schizophrenia (Heidelberg, Germany) · 2024Article
- Association of gut dysbiosis with first‑episode psychosis (Review).Molecular medicine reports · 2024Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is a chronic syndrome of unknown etiology, predominantly defined by signs of psychosis. The onset of the disorder occurs typically in late adolescence or early adulthood. Efforts to study pathophysiological mechanisms in early stages of the disease are crucial in order to prompt intervention.
methodsCase-control study of first-episode psychotic (FEP) patients and matched controls. We recruited 117 patients during the first year after their FEP according to the DSM-IV criteria and recruited 106 gender-, race-, and age-matched controls between September 2010 and June 2011.
resultsBiochemical studies carried out in peripheral mononuclear blood cells (PMBC) and plasma evidence a significant increase in intracellular components of a main proinflammatory pathway, along with a significant decrease in the anti-inflammatory ones. Multivariate logistic regression analyses identified the expression of inducible isoforms of nitric oxide synthase and cyclooxygenase in PMBC and homocysteine plasma levels as the most reliable potential risk factors and the inhibitor of the inflammatory transcription factor NFκB, IκBα, and the anti-inflammatory prostaglandin 15d-PGJ2 as potential protection factors. DISCUSSION: Taken as a whole, the results of this study indicate robust phenotypical differences at the cellular machinery level in PMBC of patients with FEP. Although more scientific evidence is needed, the determination of multiple components of pro- and anti-inflammatory cellular pathways including the activity of nuclear receptors has interesting potential as biological markers and potential risk/protective factors for FEP. Due to its soluble nature, a notable finding in this study is that the anti-inflammatory mediator 15d-PGJ2 might be used as plasmatic biomarker for first episodes of psychosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.